American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays
复制标题
DOI：
10.1200/jco.2011.36.0354
复制
发表时间：
2011-08-20
影响因子：
45.3
通讯作者：
Ajani, Jaffer A.
中科院分区：
文献类型：
--
作者：
Burstein, Harold J.;Mangu, Pamela B.;Ajani, Jaffer A.
目的更新美国临床肿瘤学会（ASCO） 2004年发表的化疗敏感性和耐药试验（CSRAs）技术评估指南。方法更新工作组回顾了2003年12月1日至2010年5月31日发表的数据。检索MEDLINE和Cochrane图书馆。文献检索产生了11313篇新文章。使用“人类和英语”的限制，然后添加随机对照试验，元分析，指南和评论的标准ASCO搜索字符串，产生1,298篇文章用于摘要综述。其中，只有21篇文章符合预定的纳入标准并进行了全文审查，其中5篇随机对照试验报告被纳入数据提取。结果：文献综述未发现任何证据基础足以支持在肿瘤学实践中使用的CSRAs。在临床试验之外，不推荐使用CSRAs来为个别患者选择化疗药物。肿瘤学家应根据已发表的临床试验报告、患者的健康状况和治疗偏好，提出化疗建议。由于体外分析策略具有潜在的重要性，参与评估这些技术的临床试验仍然是一个优先事项。[J]中华临床杂志，29(3):334 - 334。(C) 2011年美国临床肿瘤学会
Purpose To update the American Society of Clinical Oncology (ASCO) Technology Assessment guidelines on chemotherapy sensitivity and resistance assays (CSRAs) published in 2004.Methods An Update Working Group reviewed data published between December 1, 2003, and May 31, 2010. MEDLINE and the Cochrane Library were searched. The literature search yielded 11,313 new articles. The limits for "human and English" were used, and then standard ASCO search strings for randomized controlled trials, meta-analyses, guidelines, and reviews were added, yielding 1,298 articles for abstract review. Of these, only 21 articles met predefined inclusion criteria and underwent full text review, and five reports of randomized controlled trials were included for data extraction.Results Review of the literature does not identify any CSRAs for which the evidence base is sufficient to support use in oncology practice.Recommendations The use of CSRAs to select chemotherapeutic agents for individual patients is not recommended outside of the clinical trial setting. Oncologists should make chemotherapy treatment recommendations based on published reports of clinical trials and a patient's health status and treatment preferences. Because the in vitro analytic strategy has potential importance, participation in clinical trials evaluating these technologies remains a priority. J Clin Oncol 29: 3328-3330. (C) 2011 by American Society of Clinical Oncology